Clinical trial
Selinexor for the Treatment of Patients with Intermediate and High-Risk Smoldering Multiple Myeloma
NCT05597345 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Selinexor for the Treatment of Patients with Intermediate and High-Risk Smoldering Multiple Myeloma
- Lead sponsor
- University of Rochester
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 21, 2023
- Completion date
- December 31, 2025
- Enrollment
- 15 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.